Movilitas Announces Enhanced Movilitas.Cloud™ with Integrated MDLP Solution to Enable Compliance with Russia's Drug Serialization Law

Thursday, September 26, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Solution includes compliance support for pharmaceutical industry stakeholders. The new functionality can handle the longer codes from data exchange to aggregation that results from the required cryptographic key in addition to a 2D barcode and randomized serial numbers.

COLUMBIA, Md., Sept. 26, 2019 /PRNewswire-PRWeb/ -- Movilitas, a technology leader delivering the end-to-end connected

value chain of the future, announced today the availability of its enhanced Movilitas.Cloud™ solution that includes compliance support for pharmaceutical industry stakeholders. The new functionality can handle the longer codes from data exchange to aggregation that results from the required cryptographic key in addition to a 2D barcode and randomized serial numbers.

Any new medication released after January 1, 2020, must comply with Russia's Federal Law No. 425-FZ. The goal of this regulation, as with others put forth in the U.S., EU and Asia, is to reduce the occurrence of falsified medications that could affect patient safety. The Russian directive has more stringent requirements for drug serialization. It requires a different technology approach in addition to what stakeholders implemented for EU and other countries' regulations. Each group, such as manufacturers and wholesalers, must gather more data, communicate with two different Russian systems and maintain records of the transactions for auditing purposes.

The validated software as a service (SaaS) solution, Movilitas.Cloud, makes compliance for the stakeholders of the life science supply chain simple and efficient. It now includes an automatic connection to help streamline compliance by enabling communication between SAP Advanced Track and Trace for Pharmaceuticals and the Russian MDLP system for message processing and retention. Key features include:

  •     Ability to handle the longer codes from data exchange to aggregation
  •     Reporting and monitoring of 50+ transactions from manufacturing to dispensary
  •     Easily connect SAP Advanced Track and Trace for Pharmaceuticals to eliminate manual compliance processes
  •     Out-of-the-box solution with no infrastructure investment or maintenance
  •     Full control over users and devices, access reports and dashboards in one place
  •     Highly reliable with 100% availability with no unplanned downtime in over 12 months

"The pharmaceutical industry is working to meet the new requirements and manual processes even though some details have yet to be finalized," said Ross Young, CEO and President of Movilitas. "By leveraging Movilitas.Cloud's Russian MDLP functionality, we can provide our customers with a solution that meets the regulatory compliance directives of Russia's Federal Law No. 425-FZ."

To learn more about the Movilitas.Cloud Russian MDLP solution, please visit: https://www.movilitas.com/expertise/movilitascloud/russian-track-and-trace-compliance

About Movilitas Movilitas is a technology leader delivering the end-to-end connected value chain of the future. The company is recognized across diverse industries as a trusted SAP solution provider for digital supply chain transformation, with deep expertise in digital manufacturing, mobile solutions, warehouse management, and track & trace solutions. Our software as a service (SaaS) solution, Movilitas.Cloud, makes compliance for the stakeholders of the life science supply chain simple and efficient. Our expertise and solutions enable businesses to realize new opportunities of growth, adapt to today's on-demand economy and maintain compliance. Movilitas' industry and project experience are applied to each client so they can address and solve challenges faster through extensions and accelerators, such as Movilitas.Cloud, for SAP solutions. For more information, visit movilitas.com, or LinkedIn, Twitter or Xing.

 

SOURCE Movilitas



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store